Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Lynx1 Capital Management LP, a ten percent owner in Passage Bio, Inc. (NASDAQ:PASG), has recently increased its stake in the company through a series of purchases. According to a Form 4 filing with the Securities and Exchange Commission, the firm acquired a total of 31,908 shares of Passage Bio’s common stock between September 11 and September 15, 2025. The timing appears strategic, as InvestingPro analysis indicates the stock is currently trading below its Fair Value, with a strong current ratio of 3.05 showing healthy liquidity.
The purchases were executed at weighted average prices ranging from $6.9558 to $6.9908, resulting in a total transaction value of $223,734. Specifically, on September 11, Lynx1 Capital bought 325 shares at prices between $6.915 and $6.985. This was followed by the acquisition of 19,783 shares on September 12, at prices ranging from $6.93 to $7.00. The final purchase occurred on September 15, with 11,900 shares bought at prices between $6.94 and $7.00. With a beta of 1.82, InvestingPro data shows the stock exhibits significant volatility, making timing crucial for investors. Get access to 10+ additional ProTips and comprehensive analysis at InvestingPro.
Following these transactions, Lynx1 Capital Management LP now holds 623,704 shares of Passage Bio, Inc., representing a significant portion of the company’s $22.09M market capitalization. The shares are indirectly owned through Lynx1 Master Fund LP, with Lynx1 Capital Management LP acting as the investment manager. Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, disclaims beneficial ownership except to the extent of his pecuniary interest.
In other recent news, Passage Bio reported updated interim data from its Phase 1/2 upliFT-D clinical trial evaluating PBFT02, a gene therapy for frontotemporal dementia. The data revealed that patients receiving the higher dose maintained elevated cerebrospinal fluid progranulin levels 18 months after treatment. Meanwhile, the first patient treated with a lower dose showed significant increases in progranulin levels after one month. Additionally, Passage Bio’s Board of Directors approved a 1-for-20 reverse stock split effective July 14, 2025, to comply with Nasdaq’s minimum bid price requirement. This decision was backed by stockholders at the annual meeting in May. On the analyst front, Guggenheim maintained a Buy rating on Passage Bio but reduced its price target significantly from $40 to $10. Canaccord Genuity also maintained a Buy rating while lowering its price target from $260 to $67, citing an uneventful second-quarter report for 2025. These developments are part of Passage Bio’s ongoing efforts in advancing its clinical trials and maintaining compliance with market regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.